Valeant Announces Fourth-Quarter And Full-Year 2017 Results And Provides 2018 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Valeant Pharma (VRX) Setting Stage for Potential Capital Raise in 2018 - Evercore ISI's Raffat
February 28, 2018 9:50 AM ESTEvercore ISI analyst Umer Raffatt thinks Valeant Pharma (NYSE: VRX) could tap the capital market this year.
He notes while Valeant gave no clear answer on whether Valeant will look to raise capital near term and emphasized that there... More
Valeant Pharma (VRX) Posts Mixed Q4
February 28, 2018 7:05 AM ESTValeant Pharma (NYSE: VRX) reported Q4 GAAP EPS of $1.45, which may not compare to the analyst estimate of $0.97. Revenue for the quarter came in at $2.16 billion versus the consensus estimate of $2.18 billion.
Adjusted EBITDA (non-GAAP) was $875 million for the fourth quarter of 2017, as... More
